Lipid polymer hybrid nanoparticles (lipobrids) mediated delivery of aceclofenac and methotrexate modulates the breast cancer pathogenesis

Abstract

Lipid-polymer hybrid nanoparticles (LPHNPs) have emerged as one of the promising nanocarriers for various biomedical applications, including therapeutic delivery. It has been prominently investigated at preclinical level and gaining an increasing attention due to their attractive properties of drug delivery. Inflammation, one of the immune response of body’s defence mechanism, have co-relation with different cancers as it is the critical component of tumour progression. LPHNPs shows such good properties like biocompatibility, biodegradability, sustained drug release profiles, and greater loading capacity attribute to stable, high-payload targeted drug delivery vehicle that can maximize chemotherapeutic efficacy against targeted cancer cells. The formulated and characterized LPHNPs of Methotrexate and Aceclofenac with respect to size, polydispersity index(PDI), zeta potential and surface morphology were used to estimate cellular uptake, permeability and bio-distrubtion. The result have shown the less cytotoxicity, better cellular uptake & bioavailability and higher tumour targeting efficiency. The significant diminish in tumour have observed in ligand anchored LPHNPs compare to plain and MTX-LPHNPs formulation. In a nut shell, the aim of our study is to find out the effect of delivery of these drugs when delivered through novel drug delivery systems (NDDS) such as lipid polymer hybrid nanoparticles (lipobrids). Page